CD20/CD22 bispecific antibodies (Immunomedics)

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug NameCD20/CD22 bispecific antibodies (Immunomedics)

Drug Alias NameTF-5TF-3

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragmentBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionCD226 antigen blockersB-lymphocyte antigen CD20 inhibitors

TargetsCD226 antigenB-lymphocyte antigen CD20

Therapy Area/IndicationsLymphoma, Non-HodgkinLymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesImmunomedics Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesImmunomedics Inc

Active IndicationsN/A

Inactive IndicationsLymphoma, Non-HodgkinLymphoma

Other Information

ATC CodeN/A